Advertisement
UK Markets closed
  • NIKKEI 225

    39,594.39
    -4.61 (-0.01%)
     
  • HANG SENG

    17,469.36
    -166.52 (-0.94%)
     
  • CRUDE OIL

    77.03
    -1.37 (-1.75%)
     
  • GOLD FUTURES

    2,406.00
    +11.30 (+0.47%)
     
  • DOW

    40,468.55
    +53.11 (+0.13%)
     
  • BTC-GBP

    51,040.93
    -1,238.94 (-2.37%)
     
  • CMC Crypto 200

    1,356.34
    -28.92 (-2.09%)
     
  • Nasdaq

    18,046.31
    +38.74 (+0.22%)
     
  • ^FTAS

    4,479.49
    -15.97 (-0.36%)
     

CureVac First Quarter 2024 Earnings: Misses Expectations

CureVac (NASDAQ:CVAC) First Quarter 2024 Results

Key Financial Results

  • Revenue: €12.4m (up 74% from 1Q 2023).

  • Net loss: €70.6m (loss widened by 23% from 1Q 2023).

  • €0.31 loss per share (further deteriorated from €0.27 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

CureVac Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 29%.

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are up 5.7% from a week ago.

Risk Analysis

You should learn about the 3 warning signs we've spotted with CureVac (including 1 which shouldn't be ignored).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.